RAPT Q3 2022 Earnings Report
Key Takeaways
RAPT Therapeutics reported a net loss of $21.2 million for the third quarter of 2022, compared to a net loss of $18.7 million for the same period in 2021. The company's research and development expenses for the third quarter of 2022 were $16.6 million, compared to $15.7 million for the same period in 2021. As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of $195.4 million.
Net loss for the third quarter of 2022 was $21.2 million.
Research and development expenses for the third quarter of 2022 were $16.6 million.
General and administrative expenses for the third quarter of 2022 were $5.1 million.
Company had cash, cash equivalents and marketable securities of $195.4 million as of September 30, 2022.
RAPT
RAPT
Forward Guidance
RAPT Therapeutics is focused on executing and advancing both its inflammation and oncology programs.